Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma

Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma

The goal of modern neurooncological surgery is to obtain maximum tumor resection while preserving neurological function. Parietal lobe gliomas often cause attention deficits (hemineglect) that are difficult to differentiate from other deficits. This study aims to evaluate the extent and variation over time of visuo-spatial deficits in patients undergoing surgical removal of parietal lobe gliomas. This will help characterize the cognitive profile of these patients to identify personalized treatment and rehabilitation paths.

This is a single-centre, prospective, cross-sectional, observational study involving 40 patients with high- and low-grade parietal lobe glioma. The study investigates the prevalence of subjects who show a performance in cognitive visuo-spatial tests below the cut-off of the normative sample. It evaluates associations with patient-reported outcome measures (ADL, IADL), clinical-demographic aspects, radiological data (MRI), and histological/molecular data. Assessments occur at screening (pre-surgery), and at follow-up visits (3-4 months and 6 months post-surgery). Neuropsychological tests include Line Bisection, Bell and Letter Cancellation, Reading test, Apple Cancellation, and Fluff test.

Inclusion Criteria:

• Patients >18 years old
• Patients must understand the Italian Language
• Patients with suspected parietal lobe glioma

Exclusion Criteria:

• Tumor site other than parietal lobe.
• Patients who cannot undergo surgical resection (stereotactic/open biopsy).
• Patients who received a previous chemotherapy and/or radiotherapy treatment.
• Patients with a history of intracranial mass lesion or traumatic brain injury.
• Patients with a history of other CNS diseases (e.g., stroke, metastasis).
• Patients with diagnosis of neurodegenerative disease (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis).